SEC Comment Letter for Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524) (JAZZ) — Feb 20, 2020
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Date: Feb. 20, 2020 · CIK: 0001232524 · Accession: 0000000000-20-001567
AI Filing Summary & Sentiment
File numbers found in text: 001-33500
Letter
February 20, 2020 Bruce C. Cozadd Chairman and Chief Executive Officer Jazz Pharmaceuticals plc Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4 Ireland D04 E5W7 Re:Jazz Pharmaceuticals plc Form 10-K for the Fiscal Year Ended December 31, 2018 Filed February 26, 2019 File No. 001-33500 Dear Mr. Cozadd: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 20, 2020
Bruce C. Cozadd
Chairman and Chief Executive Officer
Jazz Pharmaceuticals plc
Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4
Ireland D04 E5W7
Re:Jazz Pharmaceuticals plc
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed February 26, 2019
File No. 001-33500
Dear Mr. Cozadd:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences